View in EDS

KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia.

Saved in:
Bibliographic Details
Title: KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia.
Authors: Kwon HJ; ImmunoForge, Co. Ltd, Seoul, 08591, Republic of Korea., Shin JE; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 FOUR Program, Yonsei University, Seoul, 03722, Republic of Korea., Khan A; Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA., Park SY; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 FOUR Program, Yonsei University, Seoul, 03722, Republic of Korea., Kim J; ImmunoForge, Co. Ltd, Seoul, 08591, Republic of Korea., Lee JY; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea., Lee D; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea., Lee S; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea., Im CY; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea., Moon H; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea., Han YR; Department of Chemistry, College of Science and Technology, Duksung Women'S University, Seoul, 01369, Republic of Korea., Tamai M; Department of Pediatrics, University of Yamanashi, Chuo, Japan., Akahane K; Department of Pediatrics, University of Yamanashi, Chuo, Japan.; Global Leukemia Cell-Line Assembly Network, University of Yamanashi, Kofu City, Japan., Inukai T; Department of Pediatrics, University of Yamanashi, Chuo, Japan.; Global Leukemia Cell-Line Assembly Network, University of Yamanashi, Kofu City, Japan., Lee W; Department of Chemistry, Sungkyunkwan University, Suwon, 16419, Republic of Korea., Kim H; Brain Science Institute, Korea, Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.; Department of Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea., Kim HN; Brain Science Institute, Korea, Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.; Division of Bio-Medical Science and Technology (KIST School), Korea University of Science and Technology (UST), Seoul, 02792, Republic of Korea.; School of Mechanical Engineering, Yonsei University, Seoul, 03722, Republic of Korea.; Yonsei-KIST Convergence Research Institute, Yonsei University, Seoul, 03722, Republic of Korea., Ahn SM; ImmunoForge, Co. Ltd, Seoul, 08591, Republic of Korea. ahn@immunoforge.com.; Department of Genome Medicine and Science, College of Medicine, Gachon University, Incheon, 21565, Republic of Korea. ahn@immunoforge.com., Park HW; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 FOUR Program, Yonsei University, Seoul, 03722, Republic of Korea. hwp003@yonsei.ac.kr., Kim DW; Hematology Department, Eulji Medical Center, Eulji University, Uijeongbu-Si, Gyeonggi-Do, Republic of Korea. dwkim@eulji.ac.kr.; Leukemia Omics Research Institute, Eulji University, Uijeongbu‑si, Gyeonggi‑Do, Republic of Korea. dwkim@eulji.ac.kr.
Source: Molecular cancer [Mol Cancer] 2025 Apr 14; Vol. 24 (1), pp. 114. Date of Electronic Publication: 2025 Apr 14.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40229844
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3<superscript>+</superscript> blast phase chronic myeloid leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kwon+HJ%22">Kwon HJ</searchLink>; ImmunoForge, Co. Ltd, Seoul, 08591, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Shin+JE%22">Shin JE</searchLink>; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 FOUR Program, Yonsei University, Seoul, 03722, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Khan+A%22">Khan A</searchLink>; Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.<br /><searchLink fieldCode="AU" term="%22Park+SY%22">Park SY</searchLink>; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 FOUR Program, Yonsei University, Seoul, 03722, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+J%22">Kim J</searchLink>; ImmunoForge, Co. Ltd, Seoul, 08591, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+JY%22">Lee JY</searchLink>; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+D%22">Lee D</searchLink>; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+S%22">Lee S</searchLink>; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Im+CY%22">Im CY</searchLink>; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Moon+H%22">Moon H</searchLink>; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Han+YR%22">Han YR</searchLink>; Department of Chemistry, College of Science and Technology, Duksung Women'S University, Seoul, 01369, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Tamai+M%22">Tamai M</searchLink>; Department of Pediatrics, University of Yamanashi, Chuo, Japan.<br /><searchLink fieldCode="AU" term="%22Akahane+K%22">Akahane K</searchLink>; Department of Pediatrics, University of Yamanashi, Chuo, Japan.; Global Leukemia Cell-Line Assembly Network, University of Yamanashi, Kofu City, Japan.<br /><searchLink fieldCode="AU" term="%22Inukai+T%22">Inukai T</searchLink>; Department of Pediatrics, University of Yamanashi, Chuo, Japan.; Global Leukemia Cell-Line Assembly Network, University of Yamanashi, Kofu City, Japan.<br /><searchLink fieldCode="AU" term="%22Lee+W%22">Lee W</searchLink>; Department of Chemistry, Sungkyunkwan University, Suwon, 16419, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+H%22">Kim H</searchLink>; Brain Science Institute, Korea, Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.; Department of Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+HN%22">Kim HN</searchLink>; Brain Science Institute, Korea, Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.; Division of Bio-Medical Science and Technology (KIST School), Korea University of Science and Technology (UST), Seoul, 02792, Republic of Korea.; School of Mechanical Engineering, Yonsei University, Seoul, 03722, Republic of Korea.; Yonsei-KIST Convergence Research Institute, Yonsei University, Seoul, 03722, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Ahn+SM%22">Ahn SM</searchLink>; ImmunoForge, Co. Ltd, Seoul, 08591, Republic of Korea. ahn@immunoforge.com.; Department of Genome Medicine and Science, College of Medicine, Gachon University, Incheon, 21565, Republic of Korea. ahn@immunoforge.com.<br /><searchLink fieldCode="AU" term="%22Park+HW%22">Park HW</searchLink>; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 FOUR Program, Yonsei University, Seoul, 03722, Republic of Korea. hwp003@yonsei.ac.kr.<br /><searchLink fieldCode="AU" term="%22Kim+DW%22">Kim DW</searchLink>; Hematology Department, Eulji Medical Center, Eulji University, Uijeongbu-Si, Gyeonggi-Do, Republic of Korea. dwkim@eulji.ac.kr.; Leukemia Omics Research Institute, Eulji University, Uijeongbu‑si, Gyeonggi‑Do, Republic of Korea. dwkim@eulji.ac.kr.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101147698%22">Molecular cancer</searchLink> [Mol Cancer] 2025 Apr 14; Vol. 24 (1), pp. 114. <i>Date of Electronic Publication: </i>2025 Apr 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101147698 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1476-4598 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214764598%22">14764598 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40229844
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12943-025-02292-z
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 114
    Titles:
      – TitleFull: KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kwon HJ
      – PersonEntity:
          Name:
            NameFull: Shin JE
      – PersonEntity:
          Name:
            NameFull: Khan A
      – PersonEntity:
          Name:
            NameFull: Park SY
      – PersonEntity:
          Name:
            NameFull: Kim J
      – PersonEntity:
          Name:
            NameFull: Lee JY
      – PersonEntity:
          Name:
            NameFull: Lee D
      – PersonEntity:
          Name:
            NameFull: Lee S
      – PersonEntity:
          Name:
            NameFull: Im CY
      – PersonEntity:
          Name:
            NameFull: Moon H
      – PersonEntity:
          Name:
            NameFull: Han YR
      – PersonEntity:
          Name:
            NameFull: Tamai M
      – PersonEntity:
          Name:
            NameFull: Akahane K
      – PersonEntity:
          Name:
            NameFull: Inukai T
      – PersonEntity:
          Name:
            NameFull: Lee W
      – PersonEntity:
          Name:
            NameFull: Kim H
      – PersonEntity:
          Name:
            NameFull: Kim HN
      – PersonEntity:
          Name:
            NameFull: Ahn SM
      – PersonEntity:
          Name:
            NameFull: Park HW
      – PersonEntity:
          Name:
            NameFull: Kim DW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 04
              Text: 2025 Apr 14
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1476-4598
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Molecular cancer
              Type: main
ResultId 1